Numerous studies have reported on cerebrospinal fluid (CSF) and blood biomarkers of Alzheimer’s disease (AD); however, to date, none has compared biomarker patterns across the early-onset subtypes, i.e., early onset sporadic AD (EOsAD) and autosomal dominant AD (ADAD), qualitatively and quantitatively.
Objective:
To compare the fluid biomarker patterns in early-onset subtypes of AD; EOsAD and ADAD.
Methods:
Six scientific databases were searched for peer-reviewed research publications. The total number of individuals used in all the meta-analysis were 2,427, comprised of 1,337 patients and 1,090 controls.
Results:
In the subset of EOsAD cases without APP, PSEN1/PSEN2 mutations, CSF Aβ42 and tau levels were higher when compared to the EOsAD group as a whole. Prevalence of the APOEɛ4 allele was more elevated in EOsAD relative to controls, and not significantly elevated in ADAD cases.
Conclusion:
Established CSF biomarkers confirmed quantitative differences between variants of EOAD. EOsAD is enriched with APOEɛ4, but the level is not higher than generally reported in late-onset AD. The results prompt further exploration of the etiopathogenesis of EOsAD, which accounts for ∼4–10% of all AD cases, but the reasons for the early onset remain poorly understood.
IsikAT (2010) Late onset Alzheimer’s disease in older people. Clin Interv Aging5, 307–311.
2.
DaiMH, ZhengH, ZengLD, ZhangY (2018) The genes associated with early-onset Alzheimer’s disease. Oncotarget9, 15132–15143.
3.
BatemanRJ, AisenPS, De StrooperB, FoxNC, LemereCA, RingmanJM, SallowayS, SperlingRA, WindischM, XiongC (2011) Autosomal-dominant Alzheimer’s disease: A review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther3, 1.
4.
LiberatiA, AltmanDG, TetzlaffJ, MulrowC, GøtzschePC, IoannidisJP, ClarkeM, DevereauxPJ, KleijnenJ, MoherD (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ339, b2700.
5.
VandenbrouckeJP, Von ElmE, AltmanDG, GøtzschePC, MulrowCD, PocockSJ, PooleC, SchlesselmanJJ, EggerM (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Epidemiology18, 805–835.
FleisherAS, ChenK, QuirozYT, JakimovichLJ, GomezMG, LangoisCM, LangbaumJB, RoontivaA, ThiyyaguraP, LeeW, AyutyanontN (2015) Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: A cross-sectional study. JAMA Neurol72, 316–324.
10.
LimYY, HassenstabJ, CruchagaC, GoateA, FaganAM, BenzingerTL, MaruffP, SnyderPJ, MastersCL, AllegriR, ChhatwalJ (2016) BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer’s disease. Brain139, 2766–2777.
11.
ThordardottirS, StåhlbomAK, AlmkvistO, ThonbergH, EriksdotterM, ZetterbergH, BlennowK, GraffC (2017) The effects of different familial Alzheimer’s disease mutations on APP processing. Alzheimers Res Ther9, 9.
SedgwickP (2013) Meta-analyses: How to read a funnel plot. BMJ346, f1342.
14.
SchoonenboomNS, PijnenburgYA, MulderC, RossoSM, Van ElkEJ, Van KampGJ, Van SwietenJC, ScheltensP (2004) Amyloid β42 and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology62, 1580–1584.
15.
De JongD, JansenRW, PijnenburgYA, Van GeelWJ, BormGF, KremerHP, VerbeekMM (2007) CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg78, 936–938.
16.
HozoSP, DjulbegovicB, HozoI (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol5, 13.
17.
SchöllM, WallA, ThordardottirS, FerreiraD, BogdanovicN, LångströmB, AlmkvistO, GraffC, NordbergA (2012) Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology79, 229–236.
ChowVW, MattsonMP, WongPC, GleichmannM (2010) An overview of APP processing enzymes and products. Neuromolecular Med12, 1–12.
21.
DahlgrenKN, ManelliAM, StineWB, BakerLK, KrafftGA, LaDuMJ (2002) Oligomeric and fibrillar species of amyloid β peptides differentially affect neuronal viability. J Biol Chem277, 32046–32053.
22.
JiangD, RaudaI, HanS, ChenS, ZhouF (2012) Aggregation pathways of the amyloid β42 peptide depend on its colloidal stability and ordered β-sheet stacking. Langmuir28, 12711–12721.
23.
SchupfN, TangMX, FukuyamaH, ManlyJ, AndrewsH, MehtaP, RavetchJ, MayeuxR (2018) Peripheral Aβ subspecies as risk biomarkers of Alzheimer’s disease. Proc Natl Acad Sci U S A105, 14052–14057.
24.
OlssonB, LautnerR, AndreassonU, ÖhrfeltA, PorteliusE, BjerkeM, HölttäM, RosénC, OlssonC, StrobelG, WuE (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol15, 673–684.
25.
DoreyA, Perret-LiaudetA, TholanceY, FourierA, QuadrioI (2015) Cerebrospinal fluid Aβ40 improves the interpretation of Aβ42 concentration for diagnosing Alzheimer’s disease. Front Neurol6, 247.
MandelkowEM, MandelkowE (1998) Tau in Alzheimer’s disease. Trends Cell Biol8, 425–427.
28.
HampelH, BuergerK, ZinkowskiR, TeipelSJ, GoernitzA, AndreasenN, SjoegrenM, DeBernardisJ, KerkmanD, IshiguroK, OhnoH (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry61, 95–102.
29.
AugustinackJC, SchneiderA, MandelkowEM, HymanBT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol103, 26–35.
30.
LashleyT, SchottJM, WestonP, MurrayCE, WellingtonH, KeshavanA, FotiSC, FoianiM, ToombsJ, RohrerJD, HeslegraveA (2018) Molecular biomarkers of Alzheimer’s disease: Progress and prospects. Dis Model Mech11, dmm031781.
31.
YuanA, SershenH, BasavarajappaBS, KumarA, HashimA, BergM, LeeJH, SatoY, RaoMV, MohanPS, DyakinV (2015) Neurofilament subunits are integral components of synapses and modulate neurotransmission and behavior. Mol Psychiatry20, 986–994.
32.
BaciogluM, MaiaLF, PreischeO, SchelleJ, ApelA, KaeserSA, SchweighauserM, EningerT, LambertM, PilottoA, ShimshekDR (2016) Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron91, 56–66.
33.
ZetterbergH (2016) Neurofilament light: A dynamic cross-disease fluid biomarker for neurodegeneration. Neuron91, 1–3.
34.
KesterMI, TeunissenCE, SutphenC, HerriesEM, LadensonJH, XiongC, ScheltensP, Van Der FlierWM, MorrisJC, HoltzmanDM, FaganAM (2015) Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort. Alzheimers Res Ther7, 59.
35.
Suárez-CalvetM, KleinbergerG, CaballeroMÁ, BrendelM, RomingerA, AlcoleaD, ForteaJ, LleóA, BlesaR, GispertJD, Sánchez-ValleR (2016) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer’s disease and associate with neuronal injury markers. EMBO Mol Med8, 466–476.
36.
SongF, PoljakA, ValenzuelaM, MayeuxR, SmytheGA, SachdevPS (2011) Meta-analysis of plasma amyloid-β levels in Alzheimer’s disease. J Alzheimers Dis26, 365–375.
37.
SimonsenAH, HerukkaSK, AndreasenN, BaldeirasI, BjerkeM, BlennowK, EngelborghsS, FrisoniGB, GabryelewiczT, GalluzziS, HandelsR (2017) Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement13, 274–284.
38.
ThambisettyM, LovestoneS (2010) Blood-based biomarkers of Alzheimer’s disease: Challenging but feasible. Biomark Med4, 65–79.
39.
MayeuxR, HonigLS, TangMX, ManlyJ, SternY, SchupfN, MehtaPD (2003) Plasma Aβ40 and Aβ42 and Alzheimer’s disease - Relation to age, mortality, and risk. Neurology61, 1185–1190.
40.
FindeisMA (2007) The role of amyloid β peptide 42 in Alzheimer’s disease. Pharmacol Ther116, 266–286.
41.
LundströmSL, YangH, LyutvinskiyY, RutishauserD, HerukkaSK, SoininenH, ZubarevRA (2014) Blood plasma IgG Fc glycans are significantly altered in Alzheimer’s disease and progressive mild cognitive impairment. J Alzheimers Dis38, 567–579.
42.
MuenchhoffJ, PoljakA, ThalamuthuA, GuptaVB, ChatterjeeP, RafteryM, MastersCL, MorrisJC, BatemanRJ, FaganAM, MartinsRN (2016) Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease. Sci Rep6, 29078.
43.
HongS, Beja-GlasserVF, NfonoyimBM, FrouinA, LiS, RamakrishnanS, MerryKM, ShiQ, RosenthalA, BarresBA, LemereCA (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science52, 712–716.
44.
ChungWS, VerghesePB, ChakrabortyC, JoungJ, HymanBT, UlrichJD, HoltzmanDM, BarresBA (2016) Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proc Natl Acad Sci U S A113, 10186–10191.
45.
HuynhRA, MohanC (2017) Alzheimer’s disease: Biomarkers in the genome, blood, and cerebrospinal fluid. Front Neurol8, 102.
46.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallG, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
47.
LiuCC, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
48.
FarrerLA, CupplesLA, HainesJL, HymanB, KukullWA, MayeuxR, MyersRH, Pericak-VanceMA, RischN, Van DuijnCM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta-Analysis Consortium. JAMA278, 1349–1356.
49.
VemuriP, WisteHJ, WeigandSD, KnopmanDS, ShawLM, TrojanowskiJQ, AisenPS, WeinerM, PetersenRC, JackCRJr (2010) Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol67, 308–316.
50.
IkedaM, YonemuraK, KakudaS, TashiroY, FujitaY, TakaiE, HashimotoY, MakiokaK, FurutaN, IshiguroK, MarukiR, YoshidaJ, MiyaguchiO, TsukieT, KuwanoR, YamazakiT, YamaguchiH, AmariM, TakatamaM, HarigayaY, OkamotoK (2013) Cerebrospinal fluid levels of phosphorylated tau and Aβ1–38/Aβ1–40/Aβ1–42 in Alzheimer’s disease with PS1 mutations. Amyloid20, 107–112.
